From January 1, 2024 to March 31, 2024, the company has repurchased 156,200 shares, representing 1.33% for CAD 1.31 million. With this, the company has completed the repurchase of 176,300 shares, representing 1.5% for CAD 1.48 million under the buyback announced on December 13, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.51 CAD | -3.45% | +3.59% | +3.15% |
05-17 | Tranche Update on BioSyent Inc. (TSXV:RX)'s Equity Buyback Plan announced on December 13, 2023. | CI |
05-17 | BioSyent Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.15% | 81.56M | |
+41.50% | 630B | |
-7.15% | 350B | |
+18.77% | 328B | |
+8.79% | 298B | |
+17.70% | 246B | |
+0.08% | 225B | |
+10.51% | 218B | |
+3.68% | 160B | |
-4.38% | 156B |
- Stock Market
- Equities
- RX Stock
- News BioSyent Inc.
- Tranche Update on BioSyent Inc. (TSXV: RX)'s Equity Buyback Plan announced on December 13, 2023.